“…However, tumoral location and diameter might affect the outcome, and retroperitoneal tumors tend to be larger than those occurring elsewhere [ 11 ]. A tumor larger than 10 cm is considered an important basis for judging the potential for malignancy or as a predictor of poor prognosis [ 12 ]. Fine needle aspiration biopsy can provide a preliminary diagnosis, but a definitive diagnosis requires a histopathological examination of the resected specimen.…”
“…However, tumoral location and diameter might affect the outcome, and retroperitoneal tumors tend to be larger than those occurring elsewhere [ 11 ]. A tumor larger than 10 cm is considered an important basis for judging the potential for malignancy or as a predictor of poor prognosis [ 12 ]. Fine needle aspiration biopsy can provide a preliminary diagnosis, but a definitive diagnosis requires a histopathological examination of the resected specimen.…”
“…Tumour size ≥10 cm is considered to be an important basis for judging benign and malignant tumours, or a predictor of poor metastasis prognosis, and tumour diameter greater than 7.25 cm has been shown to be associated with distant metastasis and disease-specific death. 8 SFTs are reported to have an average mass of approximately 10.6 cm, and a malignant SFT displays active tumour cell proliferation, rapid growth and large volume. For SFTs with large diameter, particularly exceeding 15 cm, the malignancy may increase, with an increased metastasis rate.…”
Solitary fibrous tumours (SFTs) usually occur at the pleura. Extrapleural sites, particularly giant extrapleural solitary fibromas, are more rarely observed in the clinic, and the clinical diagnosis and treatment of this disease is a focus of attention. Herein, the case of a 43-year-old male patient with giant presacral SFT successfully treated by open surgery, and with a final diagnosis confirmed by postoperative pathology and immunohistochemistry, is reported. The patient was followed-up regularly during 5 years after surgery, with no obvious surgical complications, and no tumour recurrence noted on pelvic magnetic resonance imaging. This case provides clinical information that may help in the diagnosis and treatment of complex SFT.
“…Solitary fibrous tumors are morphologically diverse fibroblast tumors associated with high risks of metastasis and death 4,5 . Solitary fibrous tumors can show aggressive behavior, even in the absence of any morphologic evidence of malignancy at onset 6 . Furthermore, solitary fibrous tumors that initially have benign histopathologic features can occasionally metastasize 7,8 .…”
mentioning
confidence: 99%
“… 4 , 5 Solitary fibrous tumors can show aggressive behavior, even in the absence of any morphologic evidence of malignancy at onset. 6 Furthermore, solitary fibrous tumors that initially have benign histopathologic features can occasionally metastasize. 7 , 8 FAPI PET/CT might have the potential to be used as a complementary imaging modality to identify solitary fibrous tumors.…”
Solitary fibrous tumors are fibroblast tumors that occur mainly in the peritoneum, extremities, and pleura. Here, we report the MRI, FDG PET/CT, and FAPI PET/CT findings of a rare prostate solitary fibrous tumor. A 57-year-old man was pathologically diagnosed with a solitary fibrous tumor. To detect any systemic metastases or other primary lesions, the patient underwent FDG PET/CT and FAPI PET/CTexamination sequentially. Mild FDG uptake was observed in the primary prostatic lesion, but there was a significant uptake of FAPI in the prostate. This case highlighted that FAPI PET/CT may outperform FDG PET/CT in identifying solitary fibrous tumors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.